Cargando…
Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins
Ruxolitinib is a cornerstone of management for some subsets of myeloproliferative neoplasms (MPNs); however, a considerable number of patients respond suboptimally. Here, we evaluated the efficacy of micheliolide (MCL), a natural guaianolide sesquiterpene lactone, alone or in combination with ruxoli...
Autores principales: | Huang, Huijun, Liu, Jinqin, Yang, Lin, Yan, Yiru, Chen, Meng, Li, Bing, Xu, Zefeng, Qin, Tiejun, Qu, Shiqiang, Wang, Liang, Huang, Gang, Chen, Yue, Xiao, Zhijian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629731/ https://www.ncbi.nlm.nih.gov/pubmed/37941916 http://dx.doi.org/10.1097/BS9.0000000000000168 |
Ejemplares similares
-
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017) -
ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
por: Shi, Zhongxun, et al.
Publicado: (2022) -
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015) -
Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin
por: Li, Geqiang, et al.
Publicado: (2010) -
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)